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The quality of randomization is an under-appreciated facet of trial design. The present piece represents an advance
in our collective understanding of how allocation concealment and randomization relate to risk of selection bias in
randomized trials, and other measures are also considered. Though the overwhelming majority of the advice given
is timely and correct, it is more instructive to focus on the relatively narrow sliver of advice that is incorrect (namely,
that trials should not stratify by site, and that unrestricted randomization is a solution to the problem of selection
bias), so it is in this context that the comments here must be understood. In no way is this intended to be a
rebuttal of the excellent work we have before us. Rather, it is a refinement.
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Background
Kahan, Rehal, and Cro [1] are to be congratulated for
drawing attention to a rather important problem in trial
design, namely how to reduce or eliminate the risk of
selection bias. The remedial methods discussed include
(1) masking recruiters, (2) the use of unrestricted
randomization, (3) not stratifying by site in multicenter
trials, (4) avoiding permuted blocks when stratifying by
site, and (5) making better use of prognostic covariates.
Among the major findings are that 3 % of the trials used
unrestricted randomization, 35 % did not specify how
they randomized at all, and 58 % of those that stratified
by site used permuted blocks. We wish to focus on these
findings, and also on another opportunity to curb selec-
tion bias, namely post-trial auditing as a disincentive.
The true nature of allocation concealment
It is stated that even with appropriate allocation conceal-
ment, prediction may still be possible. This misguided
statement represents a misunderstanding of allocation
concealment, and needs to be refuted since the notion is
so prevalent. As one might guess from the name itself,
allocation concealment means that the allocations are
concealed. If they can be predicted, then we do not have
appropriate allocation concealment, but, rather, have
(at best) only partial allocation concealment. Cleary,
allocation concealment is not a binary phenomenon [2],
and its success depends on addressing both threats, direct
observation and prediction. In other words, improper
randomization constitutes a violation of allocation con-
cealment [3]. These are not two distinct dimensions of
trial quality, and should not be treated as such.
Unrestricted randomization: is 3 % too much, or
too little?
The authors put forth unrestricted randomization as a
method to eliminate selection bias, and indeed it is. But
when we bear in mind that we can prevent all carpal
tunnel syndrome instantly by amputating all hands as a
preventative measure, we recognize that eliminating one
problem is not enough. The solution must also not intro-
duce additional problems. Unfortunately, unrestricted
randomization does precisely that, and this is why nobody
has ever used it, or ever would use it in an actual trial.
The 3 % is not, as suggested, too small a figure; it is, on
the contrary, too large a figure.
This may sound like an audacious claim. How can
we state that unrestricted randomization has never
been used when the authors report that 3 % figure?
In fact what is used when authors claim unrestricted
randomization is not actually unrestricted randomization,
as we shall explain. They instead use a vaguely defined
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variation we shall refer to as conditional unrestricted
randomization. One major problem with unrestricted
randomization is chronological bias, or the possibility of
many more early patients ending up in one treatment
group and many more later patients ending up in the
other treatment group [4, 5]. In fact, this chronological
bias is the primary reason that restricted randomization is
used (as it should be) [6]. However, we shall focus instead
on another issue with unrestricted randomization. Just as
a normal distribution for heights means that, sooner or
later, we will encounter an individual with a negative
height [7], so too is it the case that with true unrestricted
randomization we will, sooner or later, see an allocation
sequence comprised entirely of only one treatment group.
We do not believe that any clinical trial researcher
would ever, under any circumstances, accept such an
unfortunate outcome. If confronted by this, they would
“throw it back” and try again. But this discretion to do
that calls into question just which allocation sequences
would be considered admissible? We do not get around
this consideration by appeal to the fact that we did not
have to throw the first one back, nor by the old adage
about not being able to define it but knowing it when
we see it. In a world of precise definitions, this simply
will not cut it. Knowledge of the sampling properties of
the randomization procedure is possible only when we
actually know what the randomization procedure is. So
would we have accepted a split of 95:5? What about
90:10? Where exactly is the line drawn? And even if we
are not only OK but also thrilled with the ideal ratio of
50:50, are we still OK with a 50:50 sequence that is
segregated, with the first half of the allocations all
going to the same group, and then the rest going to
the other group to balance out the numbers at the
end? No, we are not.
Hopefully, it is clear that “unrestricted randomization”
is a procedure that nobody would ever use in an actual
clinical trial and, moreover, it is sufficiently poorly defined
that when it is claimed we cannot decipher what proced-
ure actually was used. If pressed, then a researcher who
claimed to use unrestricted randomization would have to
come to grips with just how large an imbalance in
group sizes he or she would tolerate. In fact, there is a
class of randomization procedures that explicitly takes
into account this maximally tolerated imbalance (MTI),
namely the MTI procedures, including the big stick
(essentially unrestricted randomization until the MTI
is reached, at which point the allocation is forced to
restore balance) [6], Chen’s procedure (a refinement of
the big stick in which a biasing probability is specified
so as to encourage a move towards balance without
forcing it, at least until the MTI is reached) [8], and
the maximal procedure (which selects randomly from
among the allocation sequences that adhere to the MTI
condition) [4, 5, 9]. As it turns out, these MTI procedures
are not only expressed more precisely (and honestly) than
unrestricted randomization, but they are also far more
suitable for actual trials by virtue of controlling chrono-
logical bias and eliminating the possibility of unfortunate
outcomes of the type we described earlier.
So the authors are correct in spirit. We do need
randomization procedures with fewer restrictions. But
the solution is not to swing the pendulum all the
way to the other side. We do still need some restrictions,
namely the MTI. But the call should be for no additional
restrictions above and beyond this, and also for larger
MTI values than those that are typically used in practice,
plus dropping the requirement of terminal balance.
Failure to specify how the trial was randomized
The authors are correct that failure to specify how the
trial was randomized is simply unacceptable. And yet
this occurred in 35 % of the trials evaluated. One can
only imagine a conversation between a patient (P), a
prescribing physician (PP), and a statistician (S):
P: Is this treatment you prescribed the best option
given my condition?
PP: The evidence suggests that it is.
P: I understand that medical studies are conducted to
the highest and most rigorous standards possible?
PP: Yes, they are. The stakes are too high for anything
less than the best.
P: And this is why the highest level of evidence is
reserved for randomized trials?
PP: Exactly.
P: Are all types of randomization equally rigorous, or
are some better than others?
PP: This is a question for the statistician.
S: Some methods of randomization are better than
others. The worst ones, such as permuted block
randomization, can be easily deciphered and subverted.
P: I see! Well, in that case, it’s a good thing that the
trials whose results have informed your decision on how
to treat me did not use permuted block randomization!
S: Well, they may have. We actually don’t know if they
did or didn’t.
P: I understand. I would not expect you to memorize
all the details of every study. But for my peace of mind,
can you please check on that when you go back to your
office and have the studies available?
S: No, I happen to have the articles right here with me.
It is not that I cannot remember. We do not know
because the articles did not specify how they randomized.
P: So you are telling me that they may have used a valid
randomization procedure, and they may not have? We have
no way to know? And if they didn’t, then the trial results
may bear little or no resemblance to the reality governing
how effective this treatment is for my condition?
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S: That is correct.
P: And instead of calling these authors to account, you
just assume that they randomized correctly, and then
you act accordingly in your prescribing decisions? Don’t
ask, don’t tell? Even if that means that patients may then
get exposed to harmful treatments?
And this is where our hypothetical dialogue ends, but
I would be curious to know how real physicians might
respond at this point. The enormous influence on trial
quality and the reliability of the precise method of
randomization cannot be overstated. The potential for
misleading evidence resulting from flawed randomization
methods has been well-documented [5]. And yet even
given how important this information is, over one third of
the trial authors could not be bothered to supply it, and
over one third of the journal review teams could not be
bothered to insist on it as a condition for publication. The
very essence of evidence-based medicine is trust but verify
(and that trust part is optional), yet consumers of medical
research are put in a position of having to take it on faith
that the research teams conducted rigorous research
despite the fact that these very same research teams
clearly were not rigorous at all in their reporting? This is
not even a matter of trust. Trust would be believing the
claim, but here, no claim is even offered. They do not even
claim to have randomized correctly. Credibility in a sys-
tem that allows for this cavalier attitude towards the lives
and health of actual patients might be misplaced.
Permuted blocks
It is pointed out [1] that 58 % of the stratified trials used
permuted blocks. We can all agree that this is way too
high, and the ideal proportion would be somewhere
close to zero. Even one trial using permuted blocks is
one too many. But what about trials that are not strati-
fied by center? Are permuted blocks OK in these? The
answer is still no. Just as the MTI procedures are far su-
perior to unrestricted randomization by virtue of their
better ability to handle chronological bias, so too are
they far superior to permuted block randomization, but
here due to their superior ability to control selection bias
[9, 10]. The best randomization procedure for eliminat-
ing selection bias is unrestricted randomization, yet for
the reasons articulated above, we are still opposed to its
use in practice. Might the same argument be offered to
justify using permuted block randomization even though
the MTI methods are superior? No, it cannot.
The comparison of any two randomization methods,
whether we are comparing unrestricted randomization
to the maximal procedure or whether we are comparing
blocked randomization to the big stick, must necessarily
account for both selection bias and chronological bias.
The fact that unrestricted randomization wins on only
one of these comparisons is, as we have seen, insufficient
to recommend its use, given its drawbacks on the other
dimension. But that is not the case when stating that the
MTI procedures are superior to blocked randomization.
Here, the superiority is in an overall sense, and not just
in one isolated dimension. There is no compensation by
appeal to other dimensions. The MTI procedures match
blocked randomization for control of chronological bias,
and beat it soundly for control of selection bias, in fact
in more ways than one [9]. As such, the use of permuted
block randomization is indefensible.
One reviewer pointed out that permuted block
randomization should be fine in masked trials, since
even an occasional unmasked allocation would likely
occur after the block is complete, and also for multi-
center trials for which no one investigator can keep
track of all allocations, since some will occur at other
centers. This is, in fact, a widely held view, and likely
contributes to the reluctance to switch from permuted
block randomization to MTI randomization, so it does
merit a thoughtful response.
First, in multicenter trials, randomization is generally
stratified by center, so that in fact an investigator can
keep track of how the allocation is progressing, at least
at his or her center, but then this is all that is relevant
for prediction anyway. Second, even if randomization
were not so stratified, investigators can still predict
successfully, even without certainty, based on how many
patients have so far been randomized to each group.
True, this can be done with MTI randomization too, but
then it will be less successful than it will be with
permuted blocks. Moreover, some unmasking in trials
that are planned as masked can be immediate, as with
injection site reactions [11]. And even if masking is
retained perfectly throughout, so that selection bias of
the type we consider is not an issue, there is still no
benefit in using permuted block randomization. In that
case, it is just as good as, but not better than, MTI
randomization [9]. So we are comparing two procedures,
one of which is clearly better in one situation and is just
as good in the other situation, and we would not know
ahead of time which situation we would be in.
This discussion makes clear that permuted block
randomization should not be used. It does not, however,
support the use of MTI randomization, since it would be
a false dichotomy to believe that these are the only two
options. Clearly, they are not. Proschan [12] discusses
some other types of randomization that might be used,
and, indeed, these too would be preferable to permuted
block randomization. However, in other work we have
found MTI randomization to be optimal, so it is these
procedures that we focus on, and recommend for use in
practice. Future work will extend the MTI procedures to
unequal allocation, and more than two treatment groups,
but for now, at least we can point out that it does seem
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prudent to replace permuted block randomization with
MTI randomization, at least for trials with two arms and a
1:1 allocation.
Post-trial auditing
One ideal opportunity to control selection bias was not
touched upon, but should have been. It seems pretty
close to research malpractice to not specify how the
randomization was conducted, and it is just as bad to
not formally test for selection bias after the fact. This
widespread failure to even consider selection bias allows
offending investigators to fly under the radar and to
carry on without any fear of any real consequence. There
simply is no disincentive to engage in this type of
behavior. Clearly, this needs to change if trial results are
to remain credible even after the public comes to
understand just how easy the results are to manipulate.
They will need to be assured that while it is theoretically
possible to manipulate trial results, actual trials are
immune because only best practices are used. Presently,
we are not even close to being able to claim this.
Post-trial auditing needs to be standard and routine. It
should not be triggered only when there is some basis
for suspicion [13], unless the inherent vested interests
the researchers have when conducting the trials them-
selves constitute a firm basis for suspicion, as clearly
they should. The most reliable method for testing for
selection bias in a randomized trial is the Berger-Exner
test [14], which is based on a comparative analysis of
those patients who could have been anticipated to end
up in the active treatment group versus those who ended
up there by chance. One can only wonder how many of
the trials considered conducted this analysis, although
the silence on this issue speaks volumes and we pretty
much already know the answer.
Conclusions
There is a major disconnect between the perception of
medical research as a pristine beacon of hope working
to save us all, and the reality of medical research as a
business conducted at least partially to enrich those
engage in it. Certain outcomes are more profitable, and
the trials are conducted, for the most part, by the very
parties who stand to gain or lose based on the trial
outcomes. Moreover, these same parties with the vested
interests also enjoy almost unfettered discretion to
conduct the trials as they see fit, subject to some
constraints but, as we have seen, constraints that still
allow for discretion in deciding, among other things,
to randomize properly or not. This key component of
trial quality is left as a personal decision.
Improper randomization, such as permuted block
randomization, invites the type of selection bias that can
masquerade as a treatment effect even when the
treatment in fact is no more effective than the control
(or placebo). So while inertia remains a huge problem in
getting researchers to upgrade their methodologies [15],
it is not the only problem. There is more at play here,
including a perverse system of incentives that works to
reward researchers for using flawed research method-
ology. What possible incentive do researchers have to
get it right when doing so will hurt their bottom line
and, moreover, given that it is optional anyway? Why
report honest trial results when doing so will put you at
a strategic disadvantage relative to your competitors,
some of whom may be using blocked randomization and
any other trick they can get away with?
Clearly, self-policing does not work. It is time for an
external agency to step in and clean up the mess. Only when
true accountability is demanded of all medical researchers
can we expect, first, better reporting of randomization
methods, and second, better randomization methods. The
first step has to be zero tolerance for failure to report the
randomization method used in a trial, and zero tolerance for
failure to audit the trial for selection bias after the fact. Short
of these steps, the public has every reason to withdraw
whatever trust it has left in the medical establishment.
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